uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity
Show others and affiliations
2014 (English)In: Scientific Reports, ISSN 2045-2322, E-ISSN 2045-2322, Vol. 4, 7518- p.Article in journal (Refereed) Published
Abstract [en]

Angiogenesis plays an important role in cancer and ophthalmic disorders such as age-related macular degeneration and diabetic retinopathy. The vascular endothelial growth factor (VEGF) family and corresponding receptors are regulators of angiogenesis and have been much investigated as therapeutic targets. The aim of this work was to generate antagonistic VEGFR2-specific affinity proteins having adjustable pharmacokinetic properties allowing for either therapy or molecular imaging. Two antagonistic Affibody molecules that were cross-reactive for human and murine VEGFR2 were selected by phage and bacterial display. Surprisingly, although both binders independently blocked VEGF-A binding, competition assays revealed interaction with non-overlapping epitopes on the receptor. Biparatopic molecules, comprising the two Affibody domains, were hence engineered to potentially increase affinity even further through avidity. Moreover, an albumin-binding domain was included for half-life extension in future in vivo experiments. The best-performing of the biparatopic constructs demonstrated up to 180-fold slower dissociation than the monomers. The new Affibody constructs were also able to specifically target VEGFR2 on human cells, while simultaneously binding to albumin, as well as inhibit VEGF-induced signaling. In summary, we have generated small antagonistic biparatopic Affibody molecules with high affinity for VEGFR2, which have potential for both future therapeutic and diagnostic purposes in angiogenesis-related diseases.

Place, publisher, year, edition, pages
2014. Vol. 4, 7518- p.
National Category
Biomedical Laboratory Science/Technology Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-241957DOI: 10.1038/srep07518ISI: 000346404200002OAI: oai:DiVA.org:uu-241957DiVA: diva2:782128
Available from: 2015-01-20 Created: 2015-01-19 Last updated: 2017-12-05Bibliographically approved

Open Access in DiVA

fulltext(1052 kB)89 downloads
File information
File name FULLTEXT01.pdfFile size 1052 kBChecksum SHA-512
c3ae358a858f7c0bd37b68b596b0ef374f92a127758a713cbd63c39dc858063eee404ce79b573f103d7f93249ecf075f403147b1fb9f99dafdf0c810e0c2beec
Type fulltextMimetype application/pdf

Other links

Publisher's full text
By organisation
Biomedical Radiation Sciences
In the same journal
Scientific Reports
Biomedical Laboratory Science/TechnologyCancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 89 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 363 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf